Search AXGN
Axogen, Inc.
NasdaqCM · CIK 805928
Last close37.39
Daily change-2.53 (-6.34%)
10 Years gain+319.17%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
AXGN · STANDARD
SIC 3845 · Electromedical & Electrotherapeutic Apparatus · Fiscal year end 1231
Fundamental
50.9Momentum
65.8Acceleration
65.8Confidence
77.0Annual Revenue16
Quarterly Revenue63
Annual CFO14
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth20.3 / 25
Quality13.1 / 25
Capital Efficiency0.0 / 20
Balance Sheet15.0 / 15
Shareholder Economics0.0 / 10
Forward Indicators0.0 / 5
Signals
Operating leverageOperating margin improved by 3.1684 percentage points.
Net debt reductionNet debt declined versus the comparison period.
Warnings
Heavy share dilution · HIGHDiluted share count increased 17.9966%.
Key Metrics
Revenue Growth TTM32.94%OK
Revenue CAGR 3Y17.57%OK
Gross Margin74.57%OK
Operating Margin-0.57%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROIC-0.8%OK
Incremental Operating Margin 3Y27.75%OK
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y18%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $225.21M | $167.35M | -$7.85M | $812,000.00 | -$2.93M | 74.31% | -3.49% | -1.3% | -4.89% | 46.05M |
| 2025 FY Dec 31, 2024 | $187.34M | $141.98M | -$3.29M | $4.54M | $1.43M | 75.79% | -1.75% | 0.77% | -2.27% | 44.26M |
| 2025 FY Dec 31, 2023 | $159.01M | $121.87M | -$21.46M | -$5.72M | -$19.59M | 76.64% | -13.5% | -12.32% | -16.21% | 42.88M |
| 2024 FY Dec 31, 2022 | $138.58M | $108.81M | -$29.71M | -$16.07M | -$36.14M | 78.51% | -21.44% | -26.08% | -27.42% | 42.08M |
| 2023 FY Dec 31, 2021 | $127.36M | $104.43M | -$25.42M | -$13.41M | -$41.22M | 81.99% | -19.96% | -32.36% | -32.26% | 41.21M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $247.93M | sum latest 4 fiscal quarters Revenue | OK | 0000805928-26-000094, 0000805928-25-000130 |
| Revenue Growth TTM | 32.94% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0000805928-26-000094, 0000805928-25-000130 |
| Revenue CAGR 3Y | 17.57% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0000805928-26-000031 |
| Revenue CAGR 5Y | 14.93% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0000805928-26-000031 |
| Gross Profit CAGR 3Y | 15.43% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0000805928-26-000031 |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | 0000805928-26-000094, 0000805928-25-000130 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 74.57% | Gross Profit / Revenue | OK | 0000805928-26-000094, 0000805928-25-000130 |
| Operating Margin | -0.57% | Operating Income / Revenue | OK | 0000805928-26-000094, 0000805928-25-000130 |
| ROIC | -0.8% | NOPAT / Average Invested Capital | OK | 0000805928-26-000094, 0000805928-25-000130 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0000805928-26-000094 |
| Current Ratio | 6.6x | Current Assets / Current Liabilities | OK | derived |
| Revenue per Diluted Share | $4.65 | Revenue / Diluted Shares | OK | 0000805928-26-000094, 0000805928-25-000130 |
| SBC / FCF | n/a | SBC / FCF | NOT_MEANINGFUL | derived |